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Antimicrobial properties of a long-chain, synthetic, cationic and hydrophobic amino acid block 
copolymer are reported. In 5 and 60 minute time-kill assays, solutions of K100L40 block copolymers 
(poly(L-lysine·hydrochloride)100-b-poly(L-leucine)40) at concentrations of 10 to 100 μg/mL show 
multi-log reductions in colony forming units of Gram-positive and Gram-negative bacteria, as well 
as yeast, including multidrug-resistant strains. Driven by association of hydrophobic segments, 
K100L40 copolymers form viscous solutions and self-supporting hydrogels in water at 
concentrations of 1 wt% and 2 wt%, respectively. These K100L40 preparations provide an effective 
barrier to microbial contamination of wounds, as measured by multi-log decreases of tissue-
associated bacteria with deliberate inoculation of porcine skin explants, porcine open wounds, and 
rodent closed wounds with foreign body. Based on these findings, amino acid copolymers with the 
features of K100L40 can combine potent, direct antimicrobial activity and barrier properties in one 
biopolymer for a new approach to prevention of wound infections.  
 
  
Direct antimicrobial activity and 
microbial barrier properties provided 
by a single, long-chain lysine-leucine 
block copolymer. These amino acid 
block copolymers are active against 
Gram-positive and Gram-negative 
bacteria, as well as yeast in vitro and 
form viscous solutions and hydrogels 
that can block microbial contamination 
of wounds in vivo. 
  - 3 - 
1. Introduction  
 
Human skin is a specialized organ serving to divide outside from inside.[1–4] One critical function 
is the protection of underlying tissues from microbial invasion. Skin performs this work by a 
combination of direct antimicrobial activities and microbial barrier properties. Disruption of our 
natural defenses by surgery, trauma, or disease, exposes deeper tissues to an array of microbial 
pathogens. This can set off a chain of events culminating in focal infection, and possible life-
threatening sepsis.[1,5–24] Until wound closure, prevention relies on temporary replacement of 
antimicrobial activities and barrier properties. In current standard of care, the former is typically 
provided by systemic or local antimicrobials (antibiotics and antiseptics) and the latter by wound 
dressings and bandages. Incorporation of antimicrobial agents, such as silver, into hydrogels or 
other dressings delivers both functions in a single composition.[25,26] Here, we report that both 
direct antimicrobial activities and microbial barrier properties can be designed into a single 
multifunctional biopolymer.  
 
Cationic antimicrobials, both natural and man-made, have been widely studied and are active 
ingredients in a variety of healthcare products.[27–48] While diverse in structure, cationic 
antimicrobials are unified by the display of one or more positive charges at physiologic pH that 
promote binding to multiple negatively charged structures on microbial surfaces. They include 
antiseptics, such as quaternary ammonium compounds;[28–31] biguanides (e.g. chlorhexidine and 
polihexanide);[32–35] a few antibiotics (e.g., polymyxins);[36–40] and most naturally occurring 
antimicrobial peptides (AMPs).[41–48] Cationic antimicrobials are multimodal in mechanism(s) of 
action, binding multiple molecular targets and disrupting multiple cellular functions. They are 
sometimes called “membrane active agents” because they operate, at least in part, by disrupting 
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the function and/or structure of microbial membranes. Typically, cationic antimicrobials display 
broad-spectrum effectiveness against both Gram-positive and Gram-negative bacteria.  
 
A variety of synthetic polymers have been explored as antimicrobials, and reviews of advances 
have been published.[49–52] For use of such polymers in medical settings, degradability in vivo is 
important. Recent progress has been made. For example, Hedrick and Yang have developed 
degradable antimicrobial micelles and hydrogels based on block copolymers containing carbonate 
linkages.[51,53] Synthetic cationic polypeptides, especially those containing an abundance of L-
lysine residues, can display antimicrobial activity and are attractive for their degradability.[54,55] 
Recently, this work has been expanded to include soluble statistical copolymers of lysine with 
various hydrophobic amino acids,[56] graft copolymers on other polymer or particle substrates,[57–
59] and chemically cross-linked hydrogels.[60,61] These studies point to the potential of using 
advanced synthetic biopolymers to combine antimicrobial activity with desirable chemical 
properties such as degradability. As the field progresses, additional studies will be required to 
better understand and optimize performance of antimicrobial biopolymers in vivo. 
 
In a complementary area of research, Deming and colleagues have extensively studied long-chain, 
diblock amino acid copolymers (copolypeptides) containing discrete charged and hydrophobic 
segments. These diblock amino acid copolymers can be designed to form hydrogels with tunable 
physical properties, including stiffness and porosity. They also possess other characteristics that 
may be beneficial for healthcare applications,[62–69] including  degradability in vivo,[69] 
deformability and injectability,[62] and gel formation without the need for chemical crosslinking.  
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To address the urgent need for prevention of infections in the era of antibiotic resistance, we sought 
to develop amino acid block copolymers that would be broadly antimicrobial, and would fill and 
coat tissues to prevent microbial contamination of wounds. Preliminary studies demonstrated that 
diblock amino acid copolymers, containing cationic and hydrophobic blocks, could show 
substantial antimicrobial activity.[70–73] A representative long-chain amino acid block copolymer 
of sequence poly(L-lysine·hydrochloride)100-b-poly(L-leucine)40 (K100L40; Figure 1)  was selected 
for larger scale synthesis and more detailed evaluation of properties, both in vitro and in vivo. 
Here, we report that K100L40 copolymers demonstrate direct antimicrobial activity against a broad 
array of potential pathogens in vitro, and that these same copolymers, at higher concentrations, 
make viscous solutions and hydrogels that protect wounds from microbial contamination in vivo. 
With this combination of advantageous properties, cationic and hydrophobic  amino acid block 
copolymers, including K100L40, may offer a new approach for the prevention of infections in a 
variety of settings, including the wounds of surgery, trauma, and chronic disease. 
 
2. Experimental Section 
2.1. Synthesis and chemical analysis of K100L40 amino acid block copolymers. 
 
K100L40 block copolymers were synthesized by contract manufacturer, Bachem, Inc. (Vista, CA). 
The block copolymerization was accomplished by stepwise addition of monomers to benzyl amine 
initiator under high vacuum at a low temperature.[68] Nε-trifluoroacetyl-L-lysine N-
carboxyanhydride (TFA-K NCA) (Isochem) was dissolved in a 1:1 (v:v) mixture of anhydrous 
DMAc and diglyme with an appropriate amount of initiator.  Upon completion of the first block, 
the second monomer, L-leucine N-carboxyanhydride (L NCA) (Isochem), was added in 1:1 (v:v) 
DMAc and diglyme. Once monomer consumption was complete, the protected diblock copolymers 
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were precipitated into hexanes, and then dissolved into a minimal amount of THF, and re-
precipitated into hexanes three additional times. Protected copolymers were then dried under 
vacuum. The trifluoroacetyl groups of the amino acid copolymers were deprotected using 
potassium carbonate at 50 °C in 90% MeOH. Purification was performed by tangential flow 
filtration with 5 kDa nominal molecular weight cutoff A-screen hydrophilic PES cartridges against 
pH 2 HCl (aq.), followed by pH 5 HCl (aq.) 
 
Gel permeation chromatography with multi-angle light scattering (GPC-MALS) was performed 
using differential refractive index (Wyatt Optilab T-rEX), and light scattering detectors (Wyatt 
miniDAWN TREOS), a mobile phase of hexafluoroisopropanol with 0.1% potassium 
trifluoroacetate, Jordi Gel X-Stream H2O column (mixed bed, 500 Å; Jordilabs, Mansfield, MA), 
and a flow rate of 1.0 mL/min at 45 oC. GPC analysis of the initial poly(Nε-trifluoroacetyl-L-
Lysine) chains, (TFA-K)100, showed narrow chain length distributions (typically, Mw/Mn < 1.1) 
and good agreement with target molecular weight. Comparison of chromatograms of (TFA-K)100 
and (TFA-K)100L40 showed an effective increase in molecular weight correlating to addition of the 
poly(L-leucine) segments. A chromatogram of deprotected K100L40 is shown in Supporting 
Information Figure S1.  
 
1H NMR experiments were conducted on a JEOL ECA 500 MHz NMR spectrometer at the 
University of California, San Diego. The lyophilized samples were dissolved in deuterated 
trifluoroacetic acid (d-TFA). 1H NMR analysis in d-TFA confirmed removal of trifluoroacetyl 
protecting groups, and the relative amino acid compositions of final copolymers by comparison of 
integrals of lysine and leucine resonances (Supporting Information Figure S2).  
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2.2. Mechanical analyses of K100L40 amino acid block copolymers in aqueous media.  
Samples were prepared by direct dissolution of K100L40 copolymers in sterile water (Sigma Aldrich 
W3500) at concentrations up to 30 mg/mL (3 wt%). After initial vortexing, samples were 
equilibrated at least 24 hours before additional vortexing and centrifugation (4,000 rpm, ~15 min) 
to remove air bubbles.  
 
Viscosity was assessed using calibrated Ubbelohde viscometers obtained from CANNON-
Instruments. The procedure was adapted from ASTM D 446–07. Samples of K100L40 were made 
at 0.5 and 1.0% w/w, and allowed to equilibrate at 37 °C for 30 min before being run. Each 
measurement was run in triplicate.  
 
Hydrogel formation was assessed visually in a tilt tube assay. Hydrated K100L40 copolymer samples 
at various concentrations were added to 1 dram glass vials (Scientific Specialties B69302) and 
pulse centrifuged to collect and level material. Samples were inverted and images were taken 
within 4 seconds post-inversion. Further, sample resistance to probe penetration at a defined depth, 
or firmness, was assessed by texture analysis using a TA.XT2 Texture Analyzer (Texture 
Technologies Corp, Scarsdale, NY).[74,75] In a typical experiment, a sample of K100L40 (~2 mL) 
was placed in a 5 mL polypropylene mailing tube (VWR 16465-262) at room temperature. A TA-
57 7 mm diameter stainless steel cylinder probe was then lowered into the sample at 1 mm/sec. 
The depth of the probe was normalized (depth = 0 mm) when the probe registered a positive force, 
and firmness was defined as the force at a given depth. Measurements were performed in triplicate.  
2.3. Antimicrobial studies in vitro and ex vivo.  
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2.3.1. Microbial time-kill assays in vitro.  
Time-kill assays were conducted at R.M. Alden Research Laboratory (Culver City, CA; RMA), 
based on test methods published by Clinical and Laboratory Standards Institute (CLSI M7-A7, 
M11-A8) and ASTM International (ASTM E2315-03). Laboratory strains (ATCC) and/or clinical 
isolates (RMA) were used. RMA isolates were recovered from clinical samples, identified by 
standard methods, and stored in 20% skim milk at -70 oC. Before use in studies, microbes were 
taken from the freezer and transferred at least twice on Trypticase soy agar (TSA) to ensure purity 
and good growth. Microbial aliquots were added to samples of K100L40 copolymers at different 
concentrations, and incubated for 5 or 60 minutes at room temperature. Samples were then 
neutralized and plated for Colony Forming Unit (CFU) counts. 
 
2.3.2. Antimicrobial barrier assays on porcine skin ex vivo.   
These assays were performed at iFyber (Ithaca, NY) using porcine skin obtained from a USDA 
approved facility with controlled herds. Porcine skin samples were cut into 10 mm diameter discs, 
artificially wounded with a 2 mm wide, 1.5 mm deep cavity using a Dremel tool, extensively 
washed, sterilized using chlorine gas, and washed. Explants were submersed in 1 wt% K100L40 in 
water or in water alone for 15 minutes, and placed into 24 well plates. Explants were then 
inoculated with 15 to 20 μL of 105 CFU of log-phase P. aeruginosa (ATCC BAA-47) cultures and 
incubated at 37 °C. Three hours post-inoculation, tissue explants were “washed” to remove non-
adherent bacteria by transferring to 24-well plates containing 2 mL of sterile water per well and 
placing the plates on a shaker (200 rpm) for 2 min at room temperature. The washing procedure 
was performed five times. Bacteria were recovered by individually placing explants into tubes 
containing 2 mL of Dey / Engley broth, vortexing for 10 seconds, and sonicating for 90 seconds. 
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This recovery procedure was repeated five times, with 60 seconds of rest between repeats. 20 μL 
of fluid was transferred from each tube and bacteria quantified using standard methods.  
2.4. Animal model studies.  
All animal model studies were performed by Bridge Preclinical Testing Services (PTS; San 
Antonio, TX) in a Public Health Service-assured facility. Studies had Bridge PTS Institutional 
Animal Care and Use Committee (IACUC) and US Army Medical Research and Materiel 
Command (USAMRMC) Animal Care and Use Review Office (ACURO) approvals and were 
performed in accordance to The Guide for the Care and Use of Laboratory Animals, applicable 
animal welfare regulations, and other applicable Federal and Department of Defense regulations. 
 
2.4.1. Porcine open wound model. 
Yorkshire-cross female pigs (25 to 35 kg) were housed individually and conditioned for 10 
days.[76,77] Animals were sedated by intramuscular injection of 0.05 mg/kg atropine and 4.4 mg/kg 
Telazol followed by intubation and inhalation of 2 to 5% isoflurane mixed with oxygen. The dorsal 
and lateral thorax were clipped and washed with antibacterial-free soap. Using a trephine, 12 full-
thickness wounds, 1 cm in diameter, were evenly created on each side of the thorax (24 total). An 
epinephrine solution was applied for hemostasis. Wounds were treated with 1.0 mL K100L40 (0.5, 
1.0, or 2.0 wt% in water) or water and covered in gauze soaked with 1.0 mL K100L40 or water. 
Strips of gauze sufficient to cover 12 wounds (two per pig) were then applied. Wounds were 
inoculated 15 minutes post-treatment with 108 CFU/mL of S. epidermidis, P. aeruginosa (pig 
clinical isolate), and Fusobacterium sp. (ratio of 1:1:0.5) by saturating the gauze with 60-80 mL 
of inoculum. Fusobacterium are anaerobic bacteria that support the growth of the aerobes, but are 
not measured in this model. The gauze strips were then covered with an occlusive layer of Saran 
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Wrap for 15 minutes, then both gauze and Saran Wrap were discarded. A 25 μg/hr fentanyl patch 
was provided for post-surgical pain management. Tissue biopsies (4 mm punch) were taken near 
the center of wounds and transferred to a pre-weighed vessel containing neutralizing agent. Biopsy 
samples were homogenized, serially diluted, and plated for determination of CFU. The following 
plates were used: TSA for total bacterial counts, Mannitol Salts Agar (MSA) for S. epidermidis 
counts, and Pseudomonas Isolation Agar (PIA) for P. aeruginosa counts. At the conclusion of the 
study, animals were sedated (5 mg/kg Telazol) and euthanized (110 mg/kg pentobarbital sodium).  
2.4.2. Rodent closed wound model with foreign body.   
Sprague-Dawley male rats (300-400 g) were anesthetized and a 2 cm incision made on their back. 
A blunt probe was used to create a small subcutaneous pocket into which a polypropylene mesh 
pre-soaked in K100L40 (1 wt% in water) or water was inserted. Immediately following insertion of 
pre-soaked mesh, 1 mL of K100L40 or water was applied directly into the wound pocket. Fifteen 
minutes later, wounds were inoculated with methicillin-resistant Staphylococcus aureus (MRSA; 
ATCC 33593) or P. aeruginosa (ATCC 27317) and the wound closed using Tissue Glue (3M) and 
staples. The treatment group consisted of 6 rats and the control group consisted of 8 rats. After 48 
hours post-contamination, animals were euthanized and the bacterial burden in the implanted mesh 
and surrounding tissue was assessed. 
 
3. Results & Discussion 
3.1. K100L40 solutions demonstrate antimicrobial activity in time-kill assays in vitro. 
K100L40 amino acid block copolymers were shown to be broadly antimicrobial against Gram-
positive and Gram-negative bacteria, as well as yeast. In time-kill assays with 60 minute exposures 
(Figure 2), K100L40 at 10 and 100 µg/mL in aqueous solutions caused multi-log reductions in CFU 
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of Staphylococcus aureus and Pseudomonas aeruginosa. In a broader survey, K100L40 solutions 
were shown to be active against more than a dozen microbes, including several multidrug-resistant 
(MDR) strains and clinical isolates (Table 1). Notably, at a K100L40 concentration of 100 µg/mL, 
more than 4 log reduction in CFU was observed with Acinetobacter baumannii, MDR A. 
baumannii, MDR P. aeruginosa, extended spectrum β-lactamase (ESBL) E. coli, Klebsiella 
pneumoniae, and K. pneumoniae that produce carbapenemase (KPC), all of which can cause 
clinical challenges.[78]  Microbicidal activity was also demonstrated against the yeast C. albicans 
and fluconazole-resistant C. albicans. In parallel studies, five minute exposures to 10 and 100 
μg/mL of K100L40 resulted in 1.8-2.7 log reduction in CFU of S. aureus (ATCC 6538; 2 
experiments) and 4-6 log reduction in CFU of  P. aeruginosa (ATCC 27853; 2 experiments).  
3.2. K100L40 amino acid block copolymers readily form viscous solutions and self-
supporting hydrogels. 
K100L40 copolymers in water demonstrated increased viscosity at concentrations of 0.5 wt% (5 
mg/mL) and above and formed self-supporting hydrogels at concentrations of 2 wt% and above. 
Using an Ubbelohde viscometer, K100L40 copolymers at concentrations of 0.5 and 1.0 wt% in water 
gave average values of 8.5 and 138.4 mm2/s at 37 °C, respectively; the reference value for water 
is 0.6959 mm2/s.[79] As depicted in Figure 3, both the 2 wt% and 3 wt% preparations of K100L40 
demonstrated gel formation, as assessed visually by lack of immediate flow in inverted samples. 
Quantitative texture analysis on these samples confirmed the trends observed by viscometry and 
visual assessment of gel formation. These studies indicated increasing resistance to probe 
penetration from 0.5 wt% through 3.0 wt% (Figure 3c). Overall, the formation of viscous solutions 
and hydrogels with K100L40 copolymers was found to be consistent with data on related block 
copolypeptides from the Deming lab, where physical associations of hydrophobic, 
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entantiomerically pure poly(L-leucine) segments were found to drive formation of hydrated 
networks.[53-55] 
3.3. K100L40 copolymers prepared as viscous solutions and hydrogels prevent 
microbial contamination of porcine skin explants. 
We tested the ability of K100L40 copolymer preparations to block microbial contamination of tissues 
ex vivo in a porcine skin explant model. In this study, K100L40 samples prepared as viscous 
solutions (1 wt% in water) were applied to porcine explants 15 min prior to inoculation with P. 
aeruginosa. Microbial burden was assessed in the skin explants three hours post-inoculation. As 
shown in Figure 4, more than 105 CFU P. aeruginosa were found on explants pretreated with 
water, whereas no microbes were detected on explants pretreated with K100L40 preparations. The 
studies suggest that K100L40 copolymer preparations can provide a barrier against microbial 
contamination of tissues. 
3.4. K100L40 copolymers prepared as viscous solutions and hydrogels prevent 
microbial contamination of wounds in vivo. 
The ability of K100L40 copolymer preparations to prevent microbial contamination of wounds was 
assessed in two distinct animal models. In the first model, porcine open wounds were pretreated 
with K100L40 copolymer preparations and then inoculated with a mixture of S. epidermidis and P. 
aeruginosa. As depicted in Figure 5, a single application of K100L40 (2 wt% in water) fifteen 
minutes prior to microbial inoculation resulted in a 99.99% (4 log) reduction in CFU of S. 
epidermidis (with no microbes detected) in tissue biopsies at 4 hours post-inoculation (N = 5 
wounds/group; p<0.01) compared to water controls. Reduction of tissue associated P. aeruginosa 
was also observed with the 2 wt% preparation of K100L40 (p<0.01).  
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In the second model, rodent subcutaneous pockets with foreign body (mesh) were pretreated with 
K100L40 copolymer preparations. Fifteen minutes later, wounds were inoculated with methicillin 
resistant S. aureus (MRSA) and closed. After 48 hours, the microbial burdens of wound tissues 
and mesh were assessed. As depicted in Figure 6, pretreatment with K100L40 preparations resulted 
in a 4-5 log reduction in CFU of MRSA versus control in both tissue and mesh. No microbes 
detected in wounds pretreated with K100L40 preparations. In a parallel study, multi-log reductions 
were also observed in tissue-associated and mesh-associated P. aeruginosa.  
 
Effectiveness in these two animal models, one open wound over four hours and one closed wound 
over 48 hours, suggest that K100L40 copolymer preparations can help prevent microbial 
contamination of wounds in vivo. For potential clinical applications, it may be noteworthy that the 
formation of hydrogels with K100L40 copolymers is driven primarily by association of hydrophobic 
segments, which can be disrupted by application of shear stress. This property allows these block 
copolymer preparations to pass readily through small-bore openings of common delivery devices 
(e.g., syringes, needles, or catheters) and then reform hydrogels.[62,65] Constructed from only two 
amino acids, these long-chain block copolymers are expected to show a favorable safety profile 
for local application to tissues. Beyond the scope of this paper, a series of preliminary safety studies 
in vivo have supported this expectation. Additional safety studies with K100L40 and related 
copolymers are underway. A combination of direct antimicrobial activity, barrier properties, and 
safety should enable deep tissue applications for the prevention of infections in surgery, trauma, 
and chronic wounds. 
4. Conclusions  
 
  - 14 - 
The studies presented here are based on the premise that when natural defenses are broken, the 
optimal approach combines direct antimicrobial activities and barrier properties. K100L40 
copolymer preparations were evaluated in antimicrobial studies in vitro and in vivo and found to 
be broadly active against common wound pathogens. They demonstrated direct antimicrobial 
activity at low concentrations (i.e., 10 and 100 μg/mL in water) against both Gram-positive and 
Gram-negative bacteria in vitro. Further, the design of K100L40 copolymers allowed for preparation 
and in vivo application of viscous solutions and self-supporting hydrogels (0.5 to 2 wt% in water). 
At these higher concentrations, K100L40 copolymer preparations were found to prevent microbial 
contamination of wounds. Potent, direct antimicrobial activity and barrier properties present a high 
hurdle for microbes to overcome.  
 
In this era of antibiotic resistance, new approaches for the prevention of bacterial infections are 
needed. This is urgent, especially for life-threatening infections that can occur as a result of 
surgical procedures, trauma, or chronic disease. Today’s antibiotics and antiseptics cannot fully 
address this challenge.[78,80–82] Wounds disrupt skin’s natural functions, and may become 
contaminated with a variety of microbes; it is increasingly likely that these will be multidrug-
resistant. Our goal is to replace both direct antimicrobial activities and barrier properties with a 
biocompatible material until wounds are closed by surgical procedure and/or natural healing 
processes. We believe that long-chain cationic and hydrophobic block copolypeptides, as 
exemplified here with K100L40, may achieve this goal. 
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Figure 1. Long-chain amino acid block copolymer of sequence poly(L-lysine·hydrochloride)100-
b-poly(L-leucine)40 (K100L40).   
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Figure 2. Antimicrobial activity of aqueous K100L40 against S. aureus (ATCC 6538) and P. 
aeruginosa (ATCC 27853) in vitro. Sixty minute time-kill assays were used to determine 
microbicidal activity (log CFU reduction) at different sample concentrations. Data were obtained 
from three separate experiments and are presented as mean + SD. 
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Table 1. Antimicrobial time-kill assay of K100L40 block copolymers against a variety of microbes. 
A 60 minute time-kill assay was performed with K100L40 solutions at 100 μg/mL to determine 
microbicidal activity (percent reduction of colony forming units, CFU). The term “100%” CFU 
reduction indicates that no microbes were detected. MDR=multidrug-resistant; ESBL=extended 
spectrum β-lactamase; KPC=K. pneumoniae carbapenemase. Bold = CDC “Biggest Threats”;78 
*Clinical isolates, R.M. Alden Research Laboratory. 
 
 
Microbe 
% CFU 
Reduction 
Gram positive 
S. aureus 99.99% 
MRSA* 99.97% 
Vancomycin-resistant E. faecium (VRE)* 99.94% 
S. pyogenes 99.35% 
Gram negative 
A. baumannii* 100% 
MDR A. baumannii* 100% 
ESBL E. coli* 100% 
K. pneumoniae 100% 
ESBL, KPC K. pneumoniae* 100% 
P. aeruginosa 100% 
MDR P. aeruginosa* 100% 
Anaerobe MDR B. fragilis* 99.77% 
Fungi 
C. albicans 100% 
Fluconazole-resistant C. albicans* 100% 
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Figure 3. K100L40 block copolymers form hydrogels in water. K100L40 copolymers were prepared 
in DI water at concentrations of 0.5, 1.0, 1.5, 2.0, and 3.0 wt% and assessed for gel formation by 
tilt tube assay, firmness by texture analysis, and viscosity. (a) Visual gelation study by tilt tube 
assay. (b) Concentration-dependent firmness in water as measured by texture analysis. Firmness 
values were taken at a probe depth of 8 mm. Inset picture depicts 2 wt% K100L40 in water applied 
to an artificial skin substrate (VITRO-SKIN; IMS Inc.). (c) Graphical representation showing 
change in physical properties with increasing concentration of K100L40 copolymers (white = fluid; 
black = firm gel); based on data from viscometry for 0.5 and 1.0 wt% and data from texture analysis 
and from tilt tube assay for the higher concentrations. Data were obtained from triplicate 
measurements in a single experiment and are presented as mean + SD. 
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Figure 4. Antimicrobial barrier properties of K100L40 preparations demonstrated on porcine skin 
ex vivo. (a) Data show log CFU of surviving P. aeruginosa 3 hours after inoculation of skin 
explants that were pretreated with water (control; N=8) or pretreated with 1 wt% K100L40 (N=8); 
p<0.0001. Data are presented as mean + SD. (b) Schematic of porcine explant depicting artificial 
wound. * = no microbes detected.  
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Figure 5. K100L40 preparations were found to prevent microbial contamination in a porcine open 
wound model (N = 5 wounds per group; 2 biopsies per wound). (a) S. epidermidis, (b) P. 
aeruginosa. Full-thickness wounds were pretreated with 1.0 mL of K100L40 or control (water) 15 
minutes prior to inoculation with bacteria. Wounds were then biopsied for microbial counts after 
4 hours. In both cases, the difference between control and 2% was significant at p<0.01. Data are 
presented as mean + SEM.  *No microbes detected. 
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Figure 6. K100L40 preparations (1 wt% in water) show activity against (a) MRSA (ATCC 33593) 
and (b) P. aeruginosa (ATCC 27317) in a rodent closed-wound model with foreign body (K100L40 
N=6; Control N=8; Sprague-Dawley rats). Log CFU survival shown per gram tissue for biopsy 
samples and per implanted polypropylene mesh. K100L40 preparations were applied 15 minutes 
prior to microbial inoculation; microbial burden was assessed after 48 hours. Differences between 
control and K100L40 groups for both microbes was significant at p<0.0001. Data are presented as 
mean + SEM. *No microbes detected.  
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Figure S1: GPC chromatogram showing light scattering intensity of K100L40.  
 
 
 
Figure S2:  1H NMR (d-TFA) of K100L40. 
 
 
 
 
 
 
